Acrivon Therapeutics
ACRV
ACRV
44 hedge funds and large institutions have $22.6M invested in Acrivon Therapeutics in 2026 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
less ownership
Funds ownership: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
50% less capital invested
Capital invested by funds: $44.9M → $22.6M (-$22.3M)
Holders
44
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$462K | |
| 2 | +$326K | |
| 3 | +$217K | |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$202K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$112K |
Top Sellers
| 1 | -$3.96M | |
| 2 | -$977K | |
| 3 | -$548K | |
| 4 |
Two Sigma Investments
New York
|
-$341K |
| 5 |
Millennium Management
New York
|
-$293K |
